Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02977286 · ClinicalTrials.gov registry record · Phase 4
Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids
A Phase 4 study, sponsored by Tufts Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
NCT02977286 is a Phase 4 study that was terminated before completion, run by Tufts Medical Center. The registered enrollment target is 12 participants.
The verdict
NCT02977286, a Phase 4 study, was terminated before completion, sponsored by Tufts Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study evaluates the addition of naloxegol (Movantik) to a laxative protocol in critically ill adults requiring scheduled opioid (e.g. fentanyl) therapy. Half of the participants will receive naloxegol and a laxative protocol and half the participants will receive a placebo and a laxative protocol.
Interventions
- DRUG Placebo Oral Tablet
- DRUG Naloxegol Oral Tablet
- DRUG Docusate Sodium 100 Mg oral capsule [Colace]
- DRUG Senna 217 Mg Oral Tablet
- DRUG Polyethylene Glycols
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-01-01 |
| Est. Completion | 2019-10-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02977286
The ClinicalTrials.gov registry entry for NCT02977286 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo Oral Tablet is the first listed.
NCT02977286 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02977286 about?
NCT02977286 is a clinical study titled "Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids". This study evaluates the addition of naloxegol (Movantik) to a laxative protocol in critically ill adults requiring scheduled opioid (e.g. fentanyl) therapy. Half of the participants will receive naloxegol and a laxative protocol and half the participants will receive a placebo and a laxative protoc...
What is the current status of trial NCT02977286?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2017-01-01. Estimated completion is 2019-10-09.
What interventions are being tested in trial NCT02977286?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Naloxegol Oral Tablet (DRUG), Docusate Sodium 100 Mg oral capsule [Colace] (DRUG), Senna 217 Mg Oral Tablet (DRUG), Polyethylene Glycols (DRUG).
Who is sponsoring clinical trial NCT02977286?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.